- Home
- SCHW vs GILD Comparison
SCHW vs GILD Comparison
Compare SCHW & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCHW
- GILD
- Stock Information
- Founded
- SCHW 1971
- GILD 1987
- Country
- SCHW United States
- GILD United States
- Employees
- SCHW N/A
- GILD N/A
- Industry
- SCHW Investment Bankers/Brokers/Service
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCHW Finance
- GILD Health Care
- Exchange
- SCHW Nasdaq
- GILD Nasdaq
- Market Cap
- SCHW 139.9B
- GILD 113.0B
- IPO Year
- SCHW 1987
- GILD 1992
- Fundamental
- Price
- SCHW $76.43
- GILD $91.84
- Analyst Decision
- SCHW Buy
- GILD Buy
- Analyst Count
- SCHW 15
- GILD 26
- Target Price
- SCHW $82.20
- GILD $98.17
- AVG Volume (30 Days)
- SCHW 7.7M
- GILD 6.6M
- Earning Date
- SCHW 01-21-2025
- GILD 02-11-2025
- Dividend Yield
- SCHW 1.31%
- GILD 3.35%
- EPS Growth
- SCHW N/A
- GILD N/A
- EPS
- SCHW 2.56
- GILD 0.10
- Revenue
- SCHW $18,736,000,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- SCHW $5.29
- GILD $6.50
- Revenue Next Year
- SCHW $12.91
- GILD $0.36
- P/E Ratio
- SCHW $29.85
- GILD $908.39
- Revenue Growth
- SCHW N/A
- GILD 3.31
- 52 Week Low
- SCHW $61.01
- GILD $62.07
- 52 Week High
- SCHW $83.35
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- SCHW 56.04
- GILD 51.58
- Support Level
- SCHW $71.31
- GILD $90.82
- Resistance Level
- SCHW $73.46
- GILD $93.07
- Average True Range (ATR)
- SCHW 1.50
- GILD 1.54
- MACD
- SCHW 0.32
- GILD -0.03
- Stochastic Oscillator
- SCHW 97.52
- GILD 56.28
About SCHW Charles Schwab Corporation (The)
Charles Schwab operates in brokerage, wealth management, banking, and asset management. It runs a large network of brick-and-mortar brokerage branch offices and a well-established online investing website, and it has mobile trading capabilities. It also operates a bank and a proprietary asset-management business and offers services to independent investment advisors. Schwab is among the largest firms in the investment business, with over $9 trillion of client assets at the end of September 2024. Nearly all of its revenue is from the United States.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).